ABLi Therapeutics Appoints Industry Veteran Dr. Rachelle S. Doody to its Board of Directors May 6, 2026
2026 Needham Private Company Conference Presentation demonstrating reversal of human disease process in Parkinson’s Apr 16, 2026
ABLi Therapeutics Announces Publication of the Final Results from the Phase 2 ‘201 Trial’ Evaluating Risvodetinib for the Treatment of Parkinson’s Disease Feb 20, 2026
ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial Jan 27, 2026
SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a Disease-modifying Therapy for Parkinson’s Disease Jan 5, 2026
ABLi Therapeutics Reports Final Results from the Phase 2 ‘201 Trial’ Evaluating Risvodetinib for the Treatment of Parkinson’s Disease Oct 9, 2025